SARS-CoV-2 Testing, Prevalence, and Predictors of COVID-19 in Patients with Inflammatory Bowel Disease in Northern California.
作者信息
Gubatan John, Levitte Steven, Balabanis Tatiana, Patel Akshar, Sharma Arpita, Habtezion Aida
机构信息
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California.
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California; Department of Pediatrics, Stanford University School of Medicine, Stanford, California.
出版信息
Gastroenterology. 2020 Sep;159(3):1141-1144.e2. doi: 10.1053/j.gastro.2020.05.009. Epub 2020 May 7.
Abstract
摘要
相似文献
1
SARS-CoV-2 Testing, Prevalence, and Predictors of COVID-19 in Patients with Inflammatory Bowel Disease in Northern California.
Gastroenterology. 2020 Sep;159(3):1141-1144.e2. doi: 10.1053/j.gastro.2020.05.009. Epub 2020 May 7.
2
Uneventful Course in Patients With Inflammatory Bowel Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Outbreak in Northern Italy.
Gastroenterology. 2020 Jul;159(1):371-372. doi: 10.1053/j.gastro.2020.03.062. Epub 2020 Apr 2.
3
COVID-19 in Patients With Inflammatory Bowel Disease: A Single-center Observational Study in Northern Italy.
Inflamm Bowel Dis. 2020 Oct 23;26(11):e138-e139. doi: 10.1093/ibd/izaa244.
4
Are we underestimating seroprevalence of SARS-CoV-2?
BMJ. 2020 Sep 3;370:m3364. doi: 10.1136/bmj.m3364.
5
2019 Novel Coronavirus-Important Information for Clinicians.
JAMA. 2020 Mar 17;323(11):1039-1040. doi: 10.1001/jama.2020.1490.
6
Special Issue on Diagnostic Testing for Severe Acute Respiratory Syndrome Coronavirus 2 and Lessons from This Pandemic.
J Clin Microbiol. 2020 Jul 23;58(8). doi: 10.1128/JCM.01324-20.
7
[COVID-19 and Pulmonology: New Challenges and Opportunities].
Acta Med Port. 2020 Oct 1;33(10):710. doi: 10.20344/amp.14760. Epub 2020 Sep 2.
8
Epidemiology and the Impact of Therapies on the Outcome of COVID-19 in Patients With Inflammatory Bowel Disease.
Am J Gastroenterol. 2020 Oct;115(10):1722-1724. doi: 10.14309/ajg.0000000000000830.
9
Coronavirus and Patients With Inflammatory Bowel Disease: Management Strategies for the Practicing Clinician.
Am J Gastroenterol. 2020 Oct;115(10):1566-1569. doi: 10.14309/ajg.0000000000000817.
10
Late Diagnosis of COVID-19 in Patients Admitted to the Hospital.
J Gen Intern Med. 2020 Sep;35(9):2829-2831. doi: 10.1007/s11606-020-05949-1. Epub 2020 Jun 15.
引用本文的文献
1
SARS-CoV-2 breakthrough infections after COVID-19 vaccination in patients with inflammatory bowel disease: a systematic review and meta-analysis.
Therap Adv Gastroenterol. 2023 Jul 15;16:17562848231174295. doi: 10.1177/17562848231174295. eCollection 2023.
2
Inflammatory Bowel Disease during COVID-19 Pandemic: A Prospective Cohort Study of Incidence Rate and Patients' Concerns.
Middle East J Dig Dis. 2022 Jan;14(1):24-33. doi: 10.34172/mejdd.2022.252. Epub 2022 Jan 30.
3
Inflammatory bowel disease and COVID-19 outcomes: a meta-analysis.
Sci Rep. 2022 Dec 9;12(1):21333. doi: 10.1038/s41598-022-25429-2.
4
Impact of COVID-19 on Patients with Inflammatory Bowel Disease.
J Explor Res Pharmacol. 2022 Mar;7(1):37-44. doi: 10.14218/jerp.2021.00014. Epub 2021 Oct 12.
5
Risks of SARS-CoV-2 Infection and Immune Response to COVID-19 Vaccines in Patients With Inflammatory Bowel Disease: Current Evidence.
Front Immunol. 2022 Jun 23;13:933774. doi: 10.3389/fimmu.2022.933774. eCollection 2022.
6
Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic.
Gut. 2022 Jul;71(7):1426-1439. doi: 10.1136/gutjnl-2021-326784. Epub 2022 Apr 27.
7
Impact of biologics and small molecules for inflammatory bowel disease on COVID-19-related hospitalization and mortality: A systematic review and meta-analysis.
JGH Open. 2022 Mar 20;6(4):241-250. doi: 10.1002/jgh3.12728. eCollection 2022 Apr.
8
Korean Association for the Study of Intestinal Diseases guidance for clinical practice of adult inflammatory bowel disease during the coronavirus disease 2019 pandemic: expert consensus statements.
Intest Res. 2022 Oct;20(4):431-444. doi: 10.5217/ir.2021.00111. Epub 2022 Jan 5.
9
Clinical Course of COVID-19 in Patients with Inflammatory Bowel Disease in Korea: a KASID Multicenter Study.
J Korean Med Sci. 2021 Dec 13;36(48):e336. doi: 10.3346/jkms.2021.36.e336.
10
Efficacy, Safety and Future Perspectives of JAK Inhibitors in the IBD Treatment.
J Clin Med. 2021 Nov 30;10(23):5660. doi: 10.3390/jcm10235660.
本文引用的文献
1
Liver injury in COVID-19: management and challenges.
Lancet Gastroenterol Hepatol. 2020 May;5(5):428-430. doi: 10.1016/S2468-1253(20)30057-1. Epub 2020 Mar 4.
2
The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak.
J Autoimmun. 2020 May;109:102433. doi: 10.1016/j.jaut.2020.102433. Epub 2020 Feb 26.
3
Upregulation of circulating components of the alternative renin-angiotensin system in inflammatory bowel disease: A pilot study.
J Renin Angiotensin Aldosterone Syst. 2015 Sep;16(3):559-69. doi: 10.1177/1470320314521086. Epub 2014 Feb 6.
Zotero 插件